An expert discusses how patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) now have several ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

THOUSANDS of Brits with bladder cancer could survive for twice as long after a new treatment was given the green light to be ...

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

Professor Peter Johnson, NHS England’s National Clinical Director for Cancer, said: “This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a ...

NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant breakthrough for patients facing this devastating disease.

A significant breakthrough in advanced bladder cancer treatment has been approved for use on the NHS, offering renewed hope to patients and potentially doubling survival times. The innovative ...

NHS approves new enfortumab vedotin and pembrolizumab combo for advanced bladder cancer, doubling survival rates and offering ...

SAN FRANCISCO — Pembrolizumab monotherapy exhibited antitumor activity among certain patients with high-risk non-muscle-invasive bladder cancer, according to results of a single-arm phase 2 study.

They randomly assigned 702 patients with high-risk, muscle-invasive bladder cancer who had undergone bladder-removal surgery to receive adjuvant therapy with pembrolizumab every three weeks for a ...

Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is marketed under the brand name Keytruda and is currently approved for 3 urothelial cancer indications: ...